Biotechnology decks.
5 decks from biotechnology companies, best reviewed first.

Moderna investor presentation, Analyst Day 2026
The deck opens with a title slide and a forward-looking statement, followed by an introduction from CEO Stéphane Bancel.

Moderna, Inc. investor presentation, Third Quarter 2026 earnings call
The deck opens with a title slide and a forward-looking statements disclaimer, then an agenda naming the four speakers.

Moderna investor presentation, Oncology Event, ESMO 2026
The deck opens with a cover for Moderna's oncology event dated October 2026, followed by standard forward-looking statements and an agenda listing speakers and key opinion leader perspectives.

Aerbio investor presentation, 2024
The deck opens with a title slide and then a page of investment disclaimers and representations that an investor must accept, followed by the company's one-line mission of turning carbon dioxide into protein with microbes.

Capsida Biotherapeutics investor presentation, 2025
The deck opens with a title slide and a forward-looking statements disclaimer, then frames the problem with first-generation genetic medicines: poor blood-brain barrier crossing, liver and dorsal root ganglia toxicity, narrow therapeutic windows, and risky invasive routes of delivery.